optimal health: functional medicine and nutritional genomics

AAPI’S NUTRITION GUIDE TO OPTIMAL HEALTH: USING PRINCIPLES OF FUNCTIONAL MEDICINE AND NUTRITIONAL GENOMICS PART 2
2012
Archives of Internal medicine. 2002; 162: 1237-1244.
83 Caperton EM, Heim-Duthoy KL, Matske GR, et al.
Ceftriaxone therapy of chronic inflammatory arthritis: a
double-blind placebo-controlled trial. Arch IOntern med
1990; vol 150, pp 1677-1682.
84 Schmidt MI, Duncan BB, Sharrett AR, et al. Markers
of inflammation and prediction of diabetes mellitus in
adults (Atherosclerosis Risk in Communities study): a
chort study. Lancet. 1999; vol 353, pp 1649-1652.
85 Visser M, Bouter LM, McQuillan GM, et al. Elevated
C-reactive protein levels in overweight and obese adults.
JAMA 1999; vol vol 2823, pp 2131-2135
86 Ross R. Atherosclerosis: an inflammatory disease.
New England Journal of medicine 1999; vol 340, pp
115-126.
87 Abramson JL, Vaccarino V. Relationship between
activity and inflammation among apparently healthy
middle-aged and older adults. Archives of Internal
medicine 2002; vol 162, pp 1286-1292.
88 Maes M. Major depression and activation of the
inflammatory response system. In Ctotkines, Stress and
depression, edited by danzer et al. Kluwer
Academic/Plenum Publisdhers. New York. 1999, pp 25-
46
91 Elenkov IJ, Chrousos GP. Stress hormones,
proinflammatory and anti-inflammatory cytokines, and
autoimmunity. Ann NY Acad Sci 2002; vol 966, pp 290-
303.
Petrovsky N. Towards a unified model of
neuroendocrine-immune interaction.. Immunol Cell Biol
2001; vol 79:350-7
Jessop DS, Harbuz MS, Lightman SL. CRH in chronic
inflammatory stress. Peptides 2001; vol 22,pp 803-7
Harbuz MS. Chronic inflammatory stress.. Baillieres
Best Pract Res Clin Endocrinol Metab 1999; vol 13:555-
65
Ligier S, Sternberg EM. Neuroendocrine host factors and
inflammatory disease susceptibility. Environ Health
Perspect 1999; vol 107 Suppl 5:pp 701-7
92 Raber j, Sorg 0, Horn TFW, et al . Inflammatory
cytokines: putative regulators of neuronal and neuroendocrine
function. Brain Research Reviews.1998; vol
26, pp 320–326
93 Podolsky DK. Inflammatory bbowel disease. New Eng
J med. 2002, vol 347, pp 417-429
94 Wong ML, Kling MA, Munson PJ, Listwak S, Licinio J,
Prolo P, Karp B, McCutcheon IE, Geracioti TD Jr, DeBellis
MD, Rice KC, Goldstein DS, Veldhuis JD, Chrousos GP,
Oldfield EH, McCann SM, Gold PW , Pronounced and
sustained central hypernoradrenergic function in major
depression with melancholic features: relation to
hypercortisolism and corticotropin-releasing hormone.
Proc Natl Acad Sci 2000Page:325-30
95 Maes M. et al. Lowered omega3 polyunsaturated fatty
acids in serum phospholipids and cholesteryl esters of
depressed patients. Psychiatry Res 85:275-291 (1998).
Peet M et al. Depletion of omega-3 fatty acid levels in
red blood cell membranes of depressive patients. Biol
Psychiatry 43: 315-319 (1998).
Adams PB. Arachidonic acid to eicosapentaenoic acid
ratio in blood correlates positively with clinical
symptoms of depression. Lipids 31 Suppl:S157-61 (1996)
Stoll AL, Locke CA, Marangell LB, Severus WE.Omega-3
fatty acids and bipolar disorder: a review. Prostaglandins
Leukot Essent Fatty Acids. 1999, vol 60, pp329-37..
96 www.acam.org and www.fxmed.org
97 Korsch BM, Gozzi EK, Francis V. Gaps in doctor-patient
communication. I: Doctor-patient interaction and
patient satisfaction. Pediatrics. 1968; vol 42: pp 855-
871.
98 Williams GH, Wood PHN. Common-sense beliefs
about illness: a mediating role for the doctor. Lancet.
1986; 328: 1435-1437.
99 Eisenberg L. What makes persons “patients” and
patients “well”. Amer J Med. 1980; vol 69, pp 277-286.
192